SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease

Published: 20 July 2021

  • Views:

    Views Icon 21000

  • Likes:

    Heart Icon 7

Overview

Full programme

  • Views:

    Views Icon 21000

  • Likes:

    Heart Icon 7
Part 2

of 10

Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm

Andrew JS Coats

Overview

Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders. 

 

The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.

 

In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities.  Audience questions were submitted throughout and were addressed by the panel experts.

Educational Objectives

SGLT2 Inhibition in Cardiorenal Disease

  • Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
  • Apply findings from clinical trials into clinical practice
  • Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
  • Evaluate the safety and cardiorenal benefits of glucose-lowering agents
  • Implement the new guidelines of the HFA of the ESC in clinical practice

Target Audience

  • Cardiologists
  • Nephrologists
  • Endocrinologists

More from this programme

Faculty biographies